Clinical TopicsNewsOncologyOncology Resource CenterRare Conditions

New treatment for advanced epithelioid sarcoma

By: Lydia L. Kim, Digital Content Editor

The U.S. Food and Drug Administration (FDA) recently approved Epizyme, Inc’s tazemetostat (TAZVERIK) for the treatment of adult and pediatric patients with metastatic or advanced epithelioid sarcoma (AES).

AES is a rare sarcoma that affects the soft tissue in upper extremities. The approval of tazemetostat continues to highlight the FDA’s efforts in helping increase the quality of lives of patients who suffer from rare disorders.

Please read more about the approval here. And more about AES here.


The views and opinions expressed here are those of the author and do not necessarily reflect the opinions or recommendations of the American Nurses Association, the Editorial Advisory Board members, or the Publisher, Editors and staff of American Nurse Journal. This has not been peer reviewed.

Leave a Reply

Your email address will not be published. Required fields are marked *

Fill out this field
Fill out this field
Please enter a valid email address.

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.


More Perspectives